Anti-CD20/CD3 Bispecific Monoclonal Antibody RO7082859
Anti-CD20/CD3 Bispecific Monoclonal Antibody RO7082859 Uses, Dosage, Side Effects, Food Interaction and all others data.
Anti-CD20/CD3 Bispecific Monoclonal Antibody RO7082859 is under investigation in clinical trial NCT04408638 (A Phase III Study Evaluating Anti-CD20/CD3 Bispecific Monoclonal Antibody RO7082859 in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/refractory Diffuse Large B-cell Lymphoma).
Trade Name | Anti-CD20/CD3 Bispecific Monoclonal Antibody RO7082859 |
Generic | Glofitamab |
Glofitamab Other Names | Anti-CD20/CD3 bispecific monoclonal antibody RO7082859, Glofitamab |
Type | |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | September 19, 2023 at 7:00 am |
![Anti-CD20/CD3 Bispecific Monoclonal Antibody RO7082859 Anti-CD20/CD3 Bispecific Monoclonal Antibody RO7082859](https://www.medicinesfaq.com/media/png/anti-cd20cd3-bispecific-monoclonal-antibody-ro7082859.png)
Innovators Monograph
You find simplified version here Anti-CD20/CD3 Bispecific Monoclonal Antibody RO7082859